Vincristine

Generic Name
Vincristine
Brand Names
Marqibo, Vincasar
Drug Type
Small Molecule
Chemical Formula
C46H56N4O10
CAS Number
57-22-7
Unique Ingredient Identifier
5J49Q6B70F
Background

Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...

Indication

Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma
Associated Therapies
-
Clinical Trials
Related News

Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)

First Posted Date
2005-08-15
Last Posted Date
2008-11-14
Lead Sponsor
Japan Adult Leukemia Study Group
Target Recruit Count
100
Registration Number
NCT00130195
Locations
🇯🇵

Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

First Posted Date
2005-08-03
Last Posted Date
2013-05-23
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
10
Registration Number
NCT00126191
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

First Posted Date
2005-07-11
Last Posted Date
2021-11-17
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
524
Registration Number
NCT00118209
Locations
🇺🇸

Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States

🇺🇸

Charles R. Wood Cancer Center at Glens Falls Hospital, Glens Falls, New York, United States

🇺🇸

Madigan Army Medical Center - Tacoma, Tacoma, Washington, United States

and more 44 locations

Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma

First Posted Date
2005-06-24
Last Posted Date
2022-11-18
Lead Sponsor
Trans Tasman Radiation Oncology Group
Target Recruit Count
150
Registration Number
NCT00115700
Locations
🇳🇿

Wellington Hospital, Wellington, New Zealand

🇦🇺

Royal Adelaide Hospital, Adelaide, South Australia, Australia

🇦🇺

The Canberra Hospital, Garran, Australian Capital Territory, Australia

and more 18 locations

S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

First Posted Date
2005-05-04
Last Posted Date
2015-03-25
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
79
Registration Number
NCT00109837
Locations
🇺🇸

Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States

🇺🇸

Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States

🇺🇸

Minor and James Medical, PLLC, Seattle, Washington, United States

and more 75 locations

Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma

First Posted Date
2005-01-10
Last Posted Date
2023-08-22
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
43
Registration Number
NCT00101101
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

First Posted Date
2004-09-22
Last Posted Date
2024-12-19
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
75
Registration Number
NCT00092222
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma

First Posted Date
2004-08-05
Last Posted Date
2017-05-25
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
62
Registration Number
NCT00088881
Locations
🇺🇸

Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

First Posted Date
2004-06-11
Last Posted Date
2024-02-08
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
416
Registration Number
NCT00085202
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

🇺🇸

Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston, Texas, United States

🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 6 locations

UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy

First Posted Date
2004-05-27
Last Posted Date
2015-11-23
Lead Sponsor
University of Arkansas
Target Recruit Count
668
Registration Number
NCT00083551
Locations
🇺🇸

University of Arkansas for Medical Sciences/MIRT, Little Rock, Arkansas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy